Table 2.
Age characteristics of groups | Hp-positive CD patients, % | Hp-positive non-CD controls, % | References |
---|---|---|---|
Adults | 36% | 41% | Simondi et al., 2015 |
86% (82% untreated, 95% treated) | 97% | Diamanti et al., 1999 | |
20.7% (Untreated) 32.4% (treated) | 55.3% | Ciacci et al., 2000 | |
Frequency increased with age in groups. | |||
12.5% | 30% | Lasa et al., 2015 | |
Children (age, years) | 21.8% (Median 8.2 years) | 23.8% (Median 8.9 years) | Aydogdu et al., 2008 |
18.5% (Median6.8 years) | 17.3% (Median6.8 years) | Luzza et al., 1999 | |
5.4% (3–12 years) | 6.8% (3–12 years) | Jozefczuk et al., 2015 | |
30.6 (< 18 years) | 33.8% (< 18 years) | Guz-Mark et al., 2014 | |
2.7% (Median5.7 years) | 15.6% (Median7.4 years) | Nenna et al., 2012 | |
11.4% (1–18 years) | 50% (1–18 years) | Narang et al., 2016 |